Angarone M, Snydman DR (2019) Diagnosis and management of diarrhea in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33:e13550

Article  PubMed  Google Scholar 

Yanaba K, Yoshizaki A, Asano Y, Kadono T, Tedder TF, Sato S (2011) IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol 178:735–743

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK (2002) Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16:219–230

Article  CAS  PubMed  Google Scholar 

Cavalcanti E, Armentano R, Lolli I (2020) Crohn’s disease following rituximab treatment for follicular lymphoma in a patient with synchronous gastric signet ring cells carcinoma: a case report and literature review. Cancer Res Treat 52:1291–1295

PubMed  PubMed Central  Google Scholar 

Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM (2010) Severe ulcerative colitis after rituximab therapy. Pediatrics 126:e243-246

Article  PubMed  Google Scholar 

Tsuzuki Y, Shiomi R, Ashitani K, Miyaguchi K, Osaki A, Ohgo H, Kim R, Sasaki A, Yamada T, Miyakawa Y, Nakamoto H, Imaeda H (2021) Rituximab-induced ileocolitis in a patient with gastric MALToma: a case report and literature review. Intern Med 60:731–738

Article  PubMed  PubMed Central  Google Scholar 

Iijima K, Sako M, Nozu K (2017) Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 21:193–202

Article  CAS  PubMed  Google Scholar 

Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877–919

Article  PubMed  Google Scholar 

Topaloğlu R, Gülhan B, Çelegen K, İnözü M, Hayran M, Düzova A, Ozaltin F (2019) Rituximab for children with difficult-to-treat nephrotic syndrome: its effects on disease progression and growth. Front Pediatr 7:313

Article  PubMed  PubMed Central  Google Scholar 

Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A (2015) Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 30:96–106

Article  CAS  PubMed  Google Scholar 

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281

Article  CAS  PubMed  Google Scholar 

Kallash M, Smoyer WE, Mahan JD (2019) Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr 7:178

Article  PubMed  PubMed Central  Google Scholar 

McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB (2021) Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4:e2036321

Article  PubMed  PubMed Central  Google Scholar 

Bonanni A, Calatroni M, D’Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84:1238–1249

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grenda R, Jarmużek W, Rubik J, Migdał M, Pronicki M (2015) Fatal rituximab-associated lung injury syndrome in a patient treated with rituximab for recurrence of post-transplant nephrotic syndrome. Pediatr Transplant 19:E115-120

Article  PubMed  Google Scholar 

Galassi G, Testa F, Bianchi F, Cappelli G, Chiari A (2017) Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome. CEN Case Rep 6:215–216

Article  PubMed  PubMed Central  Google Scholar 

Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834–4840

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eckmann JD, Chedid V, Quinn KP, Bonthu N, Nehra V, Raffals LE (2020) De novo colitis associated with rituximab in 21 patients at a tertiary center. Clin Gastroenterol Hepatol 18:252–253

Article  PubMed  Google Scholar 

Morita K, Shibano T, Maekawa K, Hattori M, Hida N, Nakamura S, Takeshima Y (2019) Crohn’s disease following rituximab treatment in a patient with refractory nephrotic syndrome. CEN Case Rep 8:55–60

Article  PubMed  Google Scholar 

Machida S, Kobayashi S, Yodoshi T (2022) Rituximab-induced Crohn’s disease in a child with refractory nephrotic syndrome. Pediatr Int 64:e15285

Article  PubMed  Google Scholar